secwatch.observer — SEC 8-K summary
======================================

Issuer:     Century Therapeutics, Inc. (IPSC)
CIK:        0001850119
Form:       8-K
Filed at:   2024-04-09T23:59:59+00:00
Accession:  0001104659-24-044909
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Century Therapeutics presents novel iPSC-derived cell therapy preclinical data at AACR 2024
--------------------------------------------------------------------------------

- CD19xCD22 bispecific CAR showed cytotoxicity against CD19/CD22 tumor cells in vitro and in xenograft models.
- Allo-Evasion platform: combining HLA-E and HLA-G offered best protection against NK-mediated rejection of iPSC-derived cells.
- NECTIN4-targeted iPSC-derived CAR-T demonstrated tumor inhibition comparable to Enfortumab-based CAR in OVCar-3 xenografts.
- CXCR4 transgene in iPSC-derived NK cells enhanced migration and anti-tumor efficacy in vivo, eliminating bone disease.
- Novel inhibitory CAR targeting DSG1 designed to reduce off-tumor skin toxicity of NECTIN4 therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850119/000110465924044909/0001104659-24-044909-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850119/000110465924044909/tm2411338d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-044909

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer